Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02222207
Registration number
NCT02222207
Ethics application status
Date submitted
20/08/2014
Date registered
21/08/2014
Date last updated
8/09/2016
Titles & IDs
Public title
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Query!
Scientific title
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Query!
Secondary ID [1]
0
0
2012-003763-22
Query!
Secondary ID [2]
0
0
15984
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DREAM
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Macular Degeneration
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Regorafenib, ophthalmic oily suspension (BAY73-4506)
Treatment: Surgery - Sham IVT
Treatment: Drugs - Ranibizumab
Treatment: Drugs - Placebo
Experimental: Regorafenib [A] - Part A: Patients will receive Regorafenib eye drops
Experimental: Regorafenib [B1] - Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
Experimental: Regorafenib [B2] - Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
Experimental: Regorafenib [B3] - Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
Experimental: Regorafenib [B4] - Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
Experimental: Regorafenib [B5] - Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
Experimental: Regorafenib [B6] - Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
Active comparator: Ranibizumab - Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
Treatment: Drugs: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Subjects receive Regorafenib as eye drops
Treatment: Surgery: Sham IVT
Sham injections
Treatment: Drugs: Ranibizumab
Subjects receive Ranibizumab as intravitreal injection
Treatment: Drugs: Placebo
Placebo eye drops
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Study Week 4 for Study Part A
Query!
Assessment method [1]
0
0
Participants will be assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS. The participant's ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.
Query!
Timepoint [1]
0
0
Baseline, Week 4
Query!
Primary outcome [2]
0
0
Change From Baseline in BCVA as Measured by ETDRS Letter Score at Study Week 12 for Study Part A
Query!
Assessment method [2]
0
0
Participants were assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS protocol. ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.
Query!
Timepoint [2]
0
0
Baseline, Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Individual Changes in BCVA of Greater Than Equal to (>=) 0 Letters of Vision From Study Week 4 to Week 12 for Study Part A
Query!
Assessment method [1]
0
0
Participants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.
Query!
Timepoint [1]
0
0
Week 4, Week 12
Query!
Secondary outcome [2]
0
0
Percentage of Participants With a Loss in BCVA of >= 10 Letters From Baseline to Study Week 12 for Study Part A
Query!
Assessment method [2]
0
0
Participants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.
Query!
Timepoint [2]
0
0
Baseline, Week 12
Query!
Eligibility
Key inclusion criteria
* Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) and able to understand the informed consent form (ICF)
* Men and women = 50 years of age
* Active primary subfoveal CNV (Choroidal neovascularization) lesions secondary to AMD (Age-related macular degeneration), including juxtafoveal lesions that affect the fovea as evidenced by FA (Fluorescein angiography) in the study eye and reviewed by the central reading center
* The area of CNV must occupy at least 50% of total lesion in the study eye, as determined by FA review at the central reading center
* Evidence of intraretinal and/or subretinal fluid on OCT (Optical coherence tomography)
* Early Treatment Diabetic Retinopathy Study BCVA of 73 to 25 letters (20/40 to 20/320 Snellen equivalent) in the study eye
* Willing, committed, and able to return for all clinic visits and complete all study related procedures
* Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies since signing of the ICF until one month after the EOS (end of study) visit. The definition of adequate contraception will be based on the judgment of the investigator.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Concurrent disease in the study eye, other than AMD (e.g., corneal diseases and dystrophies, conjunctival diseases, eye lid abnormalities, or any other diseases of the cornea and macula, or optic nerve abnormality) that could compromise visual acuity, likely require medical or surgical intervention during the study period, would limit the potential to gain or lose vision during study treatment, or could otherwise confound interpretation of the results
* Total lesion size (including neovascularization, scar, blood) > 12 disc areas (30.5 mm2) as assessed by FA
* Only one functional eye, even if that eye is otherwise eligible for the study
* Prior ocular or systemic treatment or surgery for neovascular AMD in the study eye except dietary supplements or vitamins
* Prior treatment with any systemic anti-VEGF (Vascular endothelial growth factor) agent
* Use of systemic or ocular treatment with an investigational drug within 12 weeks prior to start of study treatment
* Any other condition that would require frequent chronic co-administration of other topical eye medications that would interfere with study drug administration (e.g. contact lens)
* Symptoms or conditions consistent with contraindications listed in the current local label for ranibizumab
* Participation in an investigational study within 30 days prior to start of study treatment that involved treatment with any drug (excluding vitamins and minerals) or device
* Lactating women and women of child-bearing potential with either a positive pregnancy test result or no pregnancy test at screening are excluded. Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
52
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
- Strathfield
Query!
Recruitment hospital [2]
0
0
- Sydney
Query!
Recruitment hospital [3]
0
0
- Westmead
Query!
Recruitment hospital [4]
0
0
- Nedlands
Query!
Recruitment hospital [5]
0
0
- Parramatta
Query!
Recruitment postcode(s) [1]
0
0
2135 - Strathfield
Query!
Recruitment postcode(s) [2]
0
0
2000 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [5]
0
0
2150 - Parramatta
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
South Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Dakota
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Wien
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Alberta
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
British Columbia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Nova Scotia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Chile
Query!
State/province [26]
0
0
Los Lagos
Query!
Country [27]
0
0
Chile
Query!
State/province [27]
0
0
Santiago
Query!
Country [28]
0
0
Colombia
Query!
State/province [28]
0
0
Distrito Capital de Bogotá
Query!
Country [29]
0
0
Czech Republic
Query!
State/province [29]
0
0
Hradec Kralove
Query!
Country [30]
0
0
Czech Republic
Query!
State/province [30]
0
0
Praha 2
Query!
Country [31]
0
0
Czech Republic
Query!
State/province [31]
0
0
Praha 4
Query!
Country [32]
0
0
Czech Republic
Query!
State/province [32]
0
0
Praha 7
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Cedex 12
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Boredaux
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Lyon
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Baden-Württemberg
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Bayern
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Nordrhein-Westfalen
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Rheinland-Pfalz
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Sachsen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Berlin
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Hamburg
Query!
Country [43]
0
0
Hong Kong
Query!
State/province [43]
0
0
Hong Kong
Query!
Country [44]
0
0
Hong Kong
Query!
State/province [44]
0
0
Kowloon
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Budapest
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Debrecen
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Pecs
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Afula
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Beer Sheva
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Haifa
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Jerusalem
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Kfar Saba
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Petah Tikva
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Ramat Gan
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Rehovot
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Tel Aviv
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Zerifin
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Friuli-Venezia Giulia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Lazio
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Lombardia
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Toscana
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Veneto
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Ancona
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Bologna
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Milano
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Sassari
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Chiba
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Fukuoka
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Hokkaido
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Hyogo
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Kanagawa
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Mie
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Tokyo
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Kumamoto
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Nagasaki
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Nara
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Osaka
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Gyeonggido
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Busan
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Incheon
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Seoul
Query!
Country [82]
0
0
Slovakia
Query!
State/province [82]
0
0
Bratislava
Query!
Country [83]
0
0
Slovakia
Query!
State/province [83]
0
0
Ruzomberok
Query!
Country [84]
0
0
Slovakia
Query!
State/province [84]
0
0
Trencin
Query!
Country [85]
0
0
Slovakia
Query!
State/province [85]
0
0
Zilina
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Barcelona
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Vizcaya
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Albacete
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Sevilla
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Valencia
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Valladolid
Query!
Country [92]
0
0
Switzerland
Query!
State/province [92]
0
0
Bern
Query!
Country [93]
0
0
Switzerland
Query!
State/province [93]
0
0
Lausanne
Query!
Country [94]
0
0
Switzerland
Query!
State/province [94]
0
0
Zürich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study. Secondary objectives: The study will also evaluate the safety and tolerability of the regorafenib eye drops. Part B (Phase IIb): Primary objectives: The study part B is designed to investigate: * how often the regorafenib eye drops need to be given per day * whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study. Secondary objectives: The study will also evaluate how the different dosings of regorafenib eye drops affect patients vision, the safety and the tolerability.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02222207
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02222207
Download to PDF